5 billion people have access to medicine
2 billion to go

The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Quick access

Our research programmes

Access to
Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Visit this programme

Antimicrobial
Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting where good ideas are being implemented, it encourages their wider uptake.

Visit this programme

Access to
Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.

Visit this programme

View all news

Event - 20 May 2019

Jayasree K. Iyer joins panel at the 2019 Africa Pharma Conference

Starting on 4 June in Johannesburg, the conference will discuss the progress, achievements and challenges faced by African governments in developing the pharmaceutical sector, as well as best practices for catalysing local production.

View upcoming events

Publication - 16 May 2019

Ten-year analysis of pharma companies and global health

For the first time, this study assesses how the pharmaceutical industry have approached access to medicine since 2008 in 106 low- and middle-income countries – home to 83% of all people alive today.

View all publications

What leaders say

The Access to Medicine Index is a very important project. What gets measured, gets done.

Dr. Margaret Chan

Former Director General, World Health Organisation

I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged.

Mary Robinson

President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)

When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that.